Burden of Mild (<13 g/dl) Anemia in Patients With Atrial Fibrillation (A Report from a Multicenter Registry With Patient-Reported Outcomes).
暂无分享,去创建一个
K. Fukuda | S. Kohsaka | T. Fujisawa | Y. Katsumata | Y. Mano | S. Takatsuki | Takahiro Oki | Takehiro Kimura | I. Nakamura | H. Miyama | N. Ikemura | K. Hashimoto | T. Yamashita | Yoshinori Katsumata
[1] M. Hlatky,et al. Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. , 2019, European heart journal.
[2] J. Piccini,et al. Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation—Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF) , 2019, BMJ Open.
[3] K. Okumura,et al. Impact of hemoglobin concentration and platelet count on outcomes of patients with non-valvular atrial fibrillation: A subanalysis of the J-RHYTHM Registry. , 2019, International journal of cardiology.
[4] Young-Ju Kim,et al. Anemia and health-related quality of life in South Korea: data from the Korean national health and nutrition examination survey 2008–2016 , 2019, BMC Public Health.
[5] Y. Huang,et al. Safety and Effectiveness of Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study , 2019, Journal of the American Heart Association.
[6] K. Anstrom,et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial , 2019, JAMA.
[7] L. Jordaens,et al. Catheter Ablation for Atrial Fibrillation with Heart Failure , 2018, The New England journal of medicine.
[8] H. Miyata,et al. Relation of Baseline Hemoglobin Level to In-Hospital Outcomes in Patients Who Undergo Percutaneous Coronary Intervention (from a Japanese Multicenter Registry). , 2017, American Journal of Cardiology.
[9] B. Gersh,et al. No decline in the risk of heart failure after incident atrial fibrillation: A community study assessing trends overall and by ejection fraction. , 2017, Heart rhythm.
[10] R. de Caterina,et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial , 2017, American heart journal.
[11] Sally Hopewell,et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis , 2016, British Medical Journal.
[12] D. Levy,et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. , 2016, Circulation.
[13] N. Sato,et al. Association between anemia, clinical features and outcome in patients hospitalized for acute heart failure syndromes , 2015, European heart journal. Acute cardiovascular care.
[14] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[15] Emily C. O'Brien,et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation , 2015, European heart journal.
[16] S. Yusuf,et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial , 2015, Journal of thrombosis and haemostasis : JTH.
[17] E. Benjamin,et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. , 2014, European heart journal.
[18] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[19] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[20] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[21] D. Singer,et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.
[22] John Spertus,et al. Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.
[23] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[24] M. Rich,et al. Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. , 2009, American heart journal.
[25] H. Hillege,et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. , 2008, Journal of the American College of Cardiology.
[26] M. Rich,et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.
[27] L. Ferrucci,et al. Anemia Is Associated with Disability and Decreased Physical Performance and Muscle Strength in the Elderly , 2004, Journal of the American Geriatrics Society.
[28] E. Beutner,et al. Report of a WHO Scientific Group (Part 3 of 3) , 1973 .